Home › Research › Down syndrome and Alzheimer's
Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process
Cordeiro AMT, Singulani MP, Talib LL, Forlenza OV.. Journal of Alzheimer's disease : JAD, 2025-04-03
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundIndividuals with Down syndrome (DS) generally show neuropathological features of Alzheimer disease (AD). The trisomy of chromosome 21 causes an imbalance of antioxidant systems, which can be linked to AD pathophysiology.ObjectiveVerify the difference between the activity of antioxidant enzymes and products of the oxidation process in peripheral blood in non-trisomic (NT) and trisomic (DS) adults and elders and respective associations with cognitive impairment.MethodsA total of 120 subjects were included in this study. Sociodemographic and clinical information were collected as per protocol for participants in DS and NT groups. The cognitive state of the DS participants was established according to the Brazilian version of the Cambridge Examination for Mental Disorders of Older People with Down's syndrome and Others with Intellectual Disabilities (CAMDEX-DS). The CAMDEX interview was used for this purpose for participants in the NT group. Plasma samples were collected to evaluate protein carbonyl content, superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), malondialdehyde (MDA), and 4-hydroxy-2-nonenal (HNE).ResultsWe found increased levels of SOD and CAT activity in the DS group. When the groups were stratified by cognitive decline, elevated levels of SOD and CAT activity were found both in DS groups with and without decline. The activity of GPx was similar between the groups, as well as MDA and HNE.ConclusionThe results suggest that alterations of the antioxidative processes can be implicated in the onset of neurodegeneration observed in individuals with DS.
What this study adds
Evidence grade: Low
The record lists 120 participants. In 120 adults, those with Down syndrome had higher superoxide dismutase and catalase activity, while glutathione peroxidase, malondialdehyde and 4-hydroxy-2-nonenal were similar between groups. The authors suggest antioxidant changes may be involved in neurodegeneration, but no treatment, cure or prevention was tested.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cordeiro, A. M. T., Singulani, M. P., Talib, L. L., & Forlenza, O. V. (2025). Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process. Journal of Alzheimer's disease : JAD. https://doi.org/10.1177/13872877251326291
Vancouver
Cordeiro AMT, Singulani MP, Talib LL, Forlenza OV. Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process. Journal of Alzheimer's disease : JAD. 2025. doi:10.1177/13872877251326291. PMID: 40179214.
BibTeX
@article{cordeiro2025-40179214,
author = {Cordeiro, A. M. T. and Singulani, M. P. and Talib, L. L. and Forlenza, O. V.},
title = {{Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2025},
doi = {10.1177/13872877251326291},
pmid = {40179214},
url = {https://doi.org/10.1177/13872877251326291}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The activity of GPx was similar between the groups, as well as MDA and HNE.ConclusionThe results suggest that alterations of the antioxidative processes can be implicated in the onset of neurodegeneration observed in individuals with DS.
Why it matters
In 120 adults, those with Down syndrome had higher superoxide dismutase and catalase activity, while glutathione peroxidase, malondialdehyde and 4-hydroxy-2-nonenal were similar between groups. The authors suggest antioxidant changes may be involved in neurodegeneration, but no treatment, cure or prevention was tested.
Study details
- Participants120
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 120 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Orestes Vicente Forlenza: h-index 67 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universidade de São Paulo: institution h-index 936 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40179214) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.